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Summary.-Immunotherapy using rat 7s antibodies against plasmacytoma 5563
in C3H mice has been measured carefully. Prior adsorption of antibodies with
normal mouse tissues, and supplements of co-optable non-immunized macrophages
and lymphocytes enhanced the scope ofimmunotherapy against established tumours.
It is suggested that available co-optable lymphocytes and macrophages are impor-
ant limiting factors in tumour immunotherapy.
IMMUNOTHERAPY of cancer has been
the focus of many research workers in
recent years. Variable but not radical
degrees of success have been achieved.
Using specifically immune sera, Gorer
and Amos (1956) were able to protect
C57/BL mice against subsequent chal-
lenge with isogeneic leukaemia, but only
retardation of growth was obtained when
such specifically immune sera were ad-
ministered shortly after transplantation
of the tumour cells.
Such failures of antibody treatments
were followed by attempts to utilize
cellular immune mechanisms and lympho-
cytes from different animals sensitized
to the tumour were used, but again with
a limited success (Delorme and Alexander,
1964).
In our own work, an experimental
model of ascitic plasmacytoma 5563 in
C3H mice has been used where the
tumour growth has been measured
(Fakhri, 1970) and the paraprotein level
provides a reliable yardstick in follow up
(Fakhri and Hobbs, 1970a). The immune
reactions of rats to MP5563 have been
analysed. While the rat 19s antibodies
can be cytotoxic in vitro, in vivo success
was limited to the first 24 hours after
1
tumour transplantation and immunized
rat lymphocytes were unsuccessful at all
times (Fakhri and Hobbs, 1970b). Rat
7s antibodies had no direct cytotoxicity
but it was found they could co-opt
lymphocytes from unimmunized animals
to form rosettes around tumour cells
which were killed about 20 hours later
(Fakhri and Hobbs, 1972). Rat 7s anti-
bodies could also co-operate with macro-
phages, resulting in tumour cell death
within 1-2 hours. The quantitation avail-
able within the present experimental
model showed that if tumour cells were
first coated with rat 7s antibodies then
the LD50 inoculum had to be increased
by over 200 times. This increased inocu-
lum of 200,000 tumour cells presum-
ably reflected the co-optable capacity
of. the peritoneal cavity of the mouse,
and this seemed to be the limiting
factor in the present tumour immuno-
therapy.
The object of the present studies was
to see if (1) the use of rat 7s antibodies
adsorbed with normal mouse tissues
would cut down wastage and (2) if
supplements of macrophages and lympho-
cytes could bring more extensive tumours
under control.0. FAKHRI AND J. R. HOBBS
TABLE I.-Results of Treatment with Adsorbed or Unadsorbed Rat 7s Antibodies on the
Survival of Mice Implanted with Plasmacytoma 5563
Treatment
Group Antibodies Cells
A Untreated controls
B 1 ml unadsorbed
C 1 ml adsorbed
MATERIALS AND METHODS
Mouse plasmacytoma 5563 was grown in
ascitic form using intraperitoneal trans-
plantation in C3H mice from both sexes
(8-12 weeks old). Albino rats (males 3-6
months old) were used to raise antibodies
to the MP 5563. The immunization pro-
cedure, thoracic duct cannulation and pre-
paration of purified rat anti-mouse 7s anti-
bodies were as described elsewhere (Fakhri
and Hobbs, 1970a, 1972). Adsorbed 7s
anti-tumour antibodies were prepared using
4 spleens freshly collected from sacrificed
C3H mice. These were cut up and squeezed
with forceps and the washed suspension
was added to 20 ml of purified 7s anti-
bodies. The mixture was stirred for 30
minutes at room temperature and then
centrifuged to collect the supernatant.
Time after tumour
transplantation Survival
- 14±0-6 days
2 hours 14±0-6 days
2 hours 18 ±1 * 0 days
EXPERIMENTAL PROCEDURES
AND RESULTS
The in vitro activity of the 7s anti-
bodies adsorbed with mouse spleen cells
was tested. Co-option of rat lympho-
cytes to form rosettes around the tumour
cells still occurred though the adsorbed
antibody was weaker than the unad-
sorbed one.
The in vivo effects ofthe adsorbed and
unadsorbed 7s antitumour antibodies were
tested. Three groups of 5 mice (A, B
and C) were transplanted with 250,000
tumour cells each. Group A were left
untreated as controls. Two hours after
transplantation Group B were injected
intraperitoneally with 1 ml of unadsorbed
FiG. 1.-The large cell is a mouse tumour cell to which adsorbed 7s antibodies of the rat have co-opted
normal mouse small lymphocytes. x 2000.
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7s antibody and Group C were similarly
injected with 1 ml of adsorbed 7s anti-
body. The average survivals of the 3
groups are shown in Table I.
The in vivo effects of adsorbed 7s
antibodies supplemented with additional
lymphocytes and peritoneal macrophages
were then tested. In 5 groups of 5 mice
(D-H), each mouse was given 250,000
tumour cells, representing 250 times the
LD50. Group D were given no treatment
to provide controls. In Group E the
intraperitoneal treatment was 1 ml ad-
sorbed 7s antibodies together with 10
million lymphocytes collected on the
second day of drainage (when co-optable
lymphocytes are at least 40% ofthe total)
from the thoracic duct ofan unimmunized
rat. In Group F, G and H the cells
used together with the 1 ml of adsorbed
7s antibodies were from the freshly
collected peritoneal washouts of normal
mice. Each tumour-bearing mouse in
Group F was supplemented from a single
normal mouse, providing about 1 million
macrophages and about 1 million non-
immune lymphocytes, given at 24 hours
after tumour transplantation. In Group
G, H the supplement was increased
three-fold and given at 48 and 72 hours
respectively. A further control group
received one additional peritoneal wash-
out without any antibody at 24 hours
after transplantation and all died at 14
days, showing no effect from non-immune
macrophages and lymphocytes when given
alone.
DISCUSSION
The co-operations between lympho-
cytes and antibodies (Fig. 1) (Fakhri and
Hobbs, 1972) and macrophages and anti-
bodies (Fig. 2) (Fakhri, McLaughlin and
Hobbs, 1972) within the present experi-
mental model have already been reported.
FiG. 2.-The larger cells with refractile rims are the tumour cells around some of which a granular
mass of mouse macrophages have been co-opted by the adsorbed 7s antibodies. x 1000.
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TABLE II.-Prolongation ofSurvival of Mice Implanted with Plasmacytoma when Rat 7s
Antibodies were Supplemented with Cells at Different Times of Tumour Development
Treatment
, ~~~~~A
Group
D
E
Antibodies
Untreated controls
1 ml adsorbed
F 1 ml adsorbed
G 1 ml adsorbed
H 1 ml adsorbed
I Nil
Cells
10 x 106 unimmunized
rat lymphocytes
106 mouse peritoneal
macrophagest
3 x 106 mouse peritoneal
macrophagest
3 x 106 mouse peritoneal
macrophagest
106 mouse peritoneal
macrophagest
Time after tumour
transplantation
24 hours
24 hours
48 hours
72 hours
24 hours
Survival
14 days
18 days
> 200 days
> 200 days
20-35 days*
14 days
* Two mice first developed solid tumours within the peritoneal lining, then later ascites and survived
30 and 35 days respectively.
t Each 106 macrophages sample was accompanied by 106 lymphocytes also present in the peritoneal
washouts.
In both cases cell death was demonstrated
in vitro. In vivo, the mouse peritoneal
capacity was shown to cope with 200
times the LD50 of tumour cells, if such
tumour cells had first been coated with
7s antibodies before transplantation.
Macrophages were shown to be more
effective than lymphocytes as fewer cells
were needed for killing, which occurred
in a shorter time, i.e. about 1 hour,
whereas lymphocytes were required at
8-14 per tumour cell, and death did not
occur until about 20 hours later.
From the results in Table I it can be
seen that the adsorbed 7s antibodies of
the rat were more effective than the
unadsorbed. This is presumably because
the limited number ofmacrophages norm-
ally available in the peritoneal cavity
were all directed against the tumour
rather than against the normal mouse
tissues as well, as when using the unad-
sorbed antibodies. Although the tumour
MP 5563 originally arose spontaneously in
C3H mice, presumably it still has tumour
specific antigen(s) different from that of
the normal C3H mouse tissues. This was
demonstrated by the ability of the anti-
bodies to form rosettes after being ad-
sorbed with C3H cells, including normal
B-lymphocytes.
From previous studies, a doubling
time of 19 hours would suggest that a
single surviving cell would take 30 days
to grow to a tumour capable of killing
an unprotected mouse. Indeed, in all
the experiments only one mouse has
died of tumour after 30 days. That one
in Group H developed a solid tumour
within the peritoneal lining and died at
35 days. This type of change is con-
sistent with a tumour cell entering the
peritoneal wall and losing its antibody
coat before macrophages or lymphocytes
could be activated. It suggests that
solid tumours within tissues may be less
vulnerable to such co-optable cells due
to their being less readily accessible to
the tumours, and this may be even more
of a limiting factor in cancers naturally
occurring within the tissues.
The survival of mice in Group F, G
(Table II) represents a cure within the
present experimental model and Group G
mice had serum paraprotein visible on
electrophoresis, representing an amount
of tumour which we had previously
been unable to cure by immunotherapy
alone. The addition of the washout
from one normal mouse peritoneal cavity
enabled all mice to be cured at 24 hours
after transplantation, which was not
previously possible. It suggests that the
capacity of one intact normal peritoneal
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cavity (at about 200,000 coated tumour
cells), when supplemented by 106 macro-
phages, can be raised to 250,000 and their
progeny at 24 hours. With a doubling
time of 19 hours, and using adsorbed rat
antibodies to coat the tumour cells, it
seems that 106 additional macrophages
clearly cope with the additional 50,000
tumour cells and perhaps another 200,000
or so, compatible with microscopic obser-
vations of about 4-5 macrophages per
tumour cell (see Fig. 2).
The lengthening of survival from 14
to 18 days in Group C and E may not
seem impressive, but if human myelo-
matosis takes 21 years to develop from
a single cell (Hobbs, 1971) and this mouse
tumour 30 days, the 4 additional days
would be comparable to a 3-year remis-
sion in man. This is slightly better than
the average of 2 years on current chemo-
therapy.
The lengthening of survival in Group
H by 6-21 days could be considered
equivalent to remissions of 4-14 years in
man. This group is especially encourag-
ing in that by 72 hours the paraprotein
was detectable in the plasma of all mice
and at levels (ca. 0 5 g/100 ml) to which
current chemotherapy reduces human
paraproteins in some 200% of patients.
The myelomata of such patients enjoy
easy access through the rich blood supply
of the bone marrow. Therefore the
possibility of using co-opting antibodies
against human myeloma (partially ad-
sorbed with the patient's normal buffy
coat) supplemented by intravenous macro-
phages and lymphocytes (which can be
harvested from peritoneal dialysates or
using the Aminco Celltrifuge) is worthy of
exploration.
This work has been made possible
by the generous support of the Cancer
Research Campaign.
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